UCB SA (OTCMKTS:UCBJF) Receives Average Rating of “Moderate Buy” from Analysts

UCB SA (OTCMKTS:UCBJF) has received an average rating of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company.

Several equities research analysts recently weighed in on UCBJF shares. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd.

UCB Trading Down 1.9%

OTCMKTS UCBJF opened at $246.44 on Thursday. The firm has a 50 day simple moving average of $270.79 and a 200-day simple moving average of $288.60. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a one year low of $225.65 and a one year high of $345.39.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.